- Home
- IBG vs APVO Comparison
IBG vs APVO Comparison
Compare IBG & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- APVO
- Stock Information
- Founded
- IBG 2018
- APVO 2016
- Country
- IBG Australia
- APVO United States
- Employees
- IBG N/A
- APVO N/A
- Industry
- IBG Beverages (Production/Distribution)
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- IBG Consumer Staples
- APVO Health Care
- Exchange
- IBG Nasdaq
- APVO Nasdaq
- Market Cap
- IBG 5.4M
- APVO 4.1M
- IPO Year
- IBG 2024
- APVO N/A
- Fundamental
- Price
- IBG $0.57
- APVO $1.98
- Analyst Decision
- IBG Strong Buy
- APVO Strong Buy
- Analyst Count
- IBG 1
- APVO 1
- Target Price
- IBG N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- IBG 529.3K
- APVO 122.5K
- Earning Date
- IBG 08-26-2025
- APVO 08-11-2025
- Dividend Yield
- IBG N/A
- APVO N/A
- EPS Growth
- IBG N/A
- APVO N/A
- EPS
- IBG N/A
- APVO N/A
- Revenue
- IBG $2,931,243.00
- APVO N/A
- Revenue This Year
- IBG N/A
- APVO N/A
- Revenue Next Year
- IBG N/A
- APVO N/A
- P/E Ratio
- IBG N/A
- APVO N/A
- Revenue Growth
- IBG N/A
- APVO N/A
- 52 Week Low
- IBG $0.44
- APVO $1.72
- 52 Week High
- IBG $3.35
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- IBG 41.82
- APVO 32.74
- Support Level
- IBG $0.54
- APVO $1.87
- Resistance Level
- IBG $0.72
- APVO $2.07
- Average True Range (ATR)
- IBG 0.07
- APVO 0.18
- MACD
- IBG -0.01
- APVO 0.04
- Stochastic Oscillator
- IBG 10.71
- APVO 29.55
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.